Chemotherapy Near the End of Life for Chinese Patients with Solid Malignancies
| العنوان: | Chemotherapy Near the End of Life for Chinese Patients with Solid Malignancies |
|---|---|
| المؤلفون: | Lin Zhu Zhai, Wenfeng Fang, Jing Zhang, Li Zhang, Gui Nan Lin, Ning Ning Zhou, Ya Xiong Zhang, Xiao Bo He, Yan Huang, Xuan Wu, Yun Peng Yang, Hong Yun Zhao, Ning Li, Jin Sheng, Yuanyuan Zhao |
| المصدر: | The Oncologist. 22:53-60 |
| بيانات النشر: | Oxford University Press (OUP), 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Adult, Male, Oncology, China, Global Health and Cancer, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, law.invention, 03 medical and health sciences, 0302 clinical medicine, law, Neoplasms, Internal medicine, medicine, Humans, 030212 general & internal medicine, Cardiopulmonary resuscitation, Aged, Aged, 80 and over, Terminal Care, Chemotherapy, business.industry, Hazard ratio, Cancer, Retrospective cohort study, Odds ratio, Middle Aged, medicine.disease, Intensive care unit, humanities, Confidence interval, Hospice Care, 030220 oncology & carcinogenesis, Quality of Life, Female, business |
| الوصف: | Introduction There are increasing concerns about the negative impacts of chemotherapy near the end of life (EOL). There is discrepancy among different countries about its use, and little is known about the real-world situation in China. Patients and Methods This retrospective study was conducted at six representative hospitals across China. Adult decedents with a record of advanced solid cancer and palliative chemotherapy were consecutively screened from 2010 through 2014. The prevalence of EOL chemotherapy within the last 1 month of life was set as the primary outcome. The correlations among EOL chemotherapy, clinicopathological features, and overall survival (OS) were investigated. Results A total of 3,350 decedents who had had cancer were consecutively included; 2,098 (62.6%) were male and the median age was 56 years (range, 20–88). There were 177 (5.3%), 387 (11.6%), and 837 (25.0%) patients who received EOL chemotherapy within the last 2 weeks, 1 month, and 2 months of life, respectively. We identified inferior OS (median OS, 7.1 vs. 14.2 months; hazard ratio, 1.37; 95% confidence interval [CI], 1.23–1.53; p < .001), more intensive treatments (e.g., admitted to intensive care unit [ICU] in the last month of life, received cardiopulmonary resuscitation and invasive ventilation support), and hospital death (odds ratio, 1.53; 95% CI, 1.14–2.06; p = .005) among patients who received continued chemotherapy within the last month compared with those who did not. However, subgroup analyses indicated that receiving oral agents correlated with fewer ICU admissions and lower rates of in-hospital death. Conclusion This study showed that EOL chemotherapy is commonly used in China. Intravenous chemotherapy at the EOL significantly correlated with poor outcomes and the role of oral anticancer agents warrants further investigation. |
| تدمد: | 1549-490X 1083-7159 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2881f89dab5f9ea55305d9cabc1dd4eaTest https://doi.org/10.1634/theoncologist.2016-0013Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....2881f89dab5f9ea55305d9cabc1dd4ea |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1549490X 10837159 |
|---|